Don’t miss the latest developments in business and finance.

Zydus receives final approval for Tiadylt ER Capsules & Azelastine Hydrochloride Nasal Spray

Image
Capital Market
Last Updated : Aug 16 2017 | 1:01 PM IST

From USFDA

Zydus Cadila has on 16 August 2017 got final approval from the USFDA to market Tiadylt ER Capsules in stregths of 120 mg, 180 mg, 240 mg, 300 mg, 360 mg and 420 mg, and also to market Azelastine Hydrochloride Nasal Spray 137 mg.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Aug 16 2017 | 12:47 PM IST

Next Story